Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2019 16:01 ET | Source: Dermira, Inc.

Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Conference

MENLO PARK, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
February 19, 2019 16:01 ET | Source: Dermira, Inc.

Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019

MENLO PARK, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
February 12, 2019 02:00 ET | Source: Dermira, Inc.

Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab

- Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe- Dermira to receive an option fee of $30 million- Lebrikizumab is an...
December 11, 2018 17:07 ET | Source: Dermira, Inc.

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MENLO PARK, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
December 04, 2018 07:30 ET | Source: Dermira, Inc.

Dermira Enters into Credit Facility with Athyrium Capital Management

MENLO PARK, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
November 19, 2018 08:00 ET | Source: Dermira, Inc.

Dermira to Present at Evercore ISI HealthCONx Conference

MENLO PARK, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
November 08, 2018 16:05 ET | Source: Dermira, Inc.

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MENLO PARK, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
November 07, 2018 16:01 ET | Source: Dermira, Inc.

Dermira Reports Third Quarter 2018 Financial Results

Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing...
October 31, 2018 16:01 ET | Source: Dermira, Inc.

Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018

MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
October 23, 2018 16:01 ET | Source: Dermira, Inc.

Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Topline efficacy and safety results anticipated by early April 2019 MENLO PARK, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right